News & Videos - NOVARTIS N

EQS-News: Novartis Pharma GmbH / Schlagwort(e): Kooperation Mit Cholesterin-Screening dem Herzinfarkt und Schlaganfall vorbeugen: Novartis und die Charité erarbeiten neues Versorgungskonzept 19.04.2024 / 10:15 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Mit Cholesterin-Screening dem Herzinfarkt und Schlaganfall vorbeugen: Novartis und die Charité erarbeiten neues Versorgungskonzept Neues Präventionsmodell soll in Kooperation mit dem Friede Springer...

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) PR Newswire EAST HANOVER, N.J., April 15, 2024 APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN 1 IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease...

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting PR Newswire EAST HANOVER, N.J., April 6, 2024 V- INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7%...

If the healthcare industry was a country, it would be the fifth largest polluter on Earth. In the latest episode of The Big Question, ......

EQS-News: Novartis Pharma GmbH / Schlagwort(e): Sonstiges Startschuss für den Digitalen Gesundheitspreis 2024: Novartis sucht auch in diesem Jahr Health-Tech-Projekte 01.02.2024 / 10:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Startschuss für den Digitalen Gesundheitspreis 2024: Novartis sucht auch in diesem Jahr Health-Tech-Projekte Bis zum 29. Februar können sich Gründer*innen mit innovativen Health-Tech- Projekten für den mit insgesamt 60.000...

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis PR Newswire SHANGHAI, Jan. 7, 2024 - Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. - Novartis will receive an ex- Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worldwide exclusive license for a Phase 1 stage cardiovascular asset as well...

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH NOVARTIS PR Newswire LONDON, Jan. 7, 2024 Isomorphic Labs to Receive $37.5 Million Upfront Payment From Novartis to Collaborate on Small Molecule Therapeutics Discovery LONDON , Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with...

FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrally located in the US to maximize access for patients and treatment centers With four active RLT manufacturing sites and unconstrained supply, Novartis can sufficiently meet current and future demand as ongoing clinical trials...

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) PR Newswire EAST HANOVER, N.J., Dec. 10, 2023 APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved...

APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigue in the majority of patients, with a safety profile consistent with previously reported data 1 - 5 Patients switching from anti-C5s to Fabhalta in the extension period achieved outcomes comparable to the Fabhalta arm in the...

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% and 24.5%, respectively 1, 2 Latest analysis continues to show a well-tolerated safety profile in line...

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH PR Newswire EAST HANOVER, N.J., Dec. 5, 2023 Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients 1-5 In APPLY-PNH, patients who switched to Fabhalta experienced superior increases of hemoglobin...

Ad hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients 1- 5 In APPLY-PNH, patients who switched to Fabhalta experienced superior increases of hemoglobin levels ≥ 2 g/dL (82.3% vs. 0%) and hemoglobin level ≥ 12 g/dL (67.7% vs. 0%), both in the absence of red blood cell transfusions, vs. patients who continued on anti-C5 treatment 1...

Late-breaking final iDFS analysis from NATALEE investigating Kisqali ® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-negative disease New 48-week efficacy and safety data from the Phase III APPLY-PNH trial of investigational oral monotherapy iptacopan in anti-C5-treated adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia Nearly 4 year follow-up efficacy and safety results from end of...

Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization PR Newswire EAST HANOVER, N.J., Sept. 11, 2023 Company Contact: Novartis Pharmaceuticals Corporation 1-888-669-6682 EAST HANOVER, N.J. , Sept. 11, 2023 /PRNewswire/ -- Novartis is conducting a voluntary nationwide recall at the consumer level of one lot of its Sandimmune ® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due...

Thinking about trading options or stock in NVIDIA, SoundHound AI, Novartis, Faraday Future Intelligent Electric, or Medical Properties Trust? PR Newswire NEW YORK, Aug. 30, 2023 NEW YORK , Aug. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVDA, SOUN, NVS, FFIE, and MPW. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The...

Unither Pharmaceuticals has completed the purchase of the Novartis site located at Butantã, in São Paulo, Brazil PR Newswire PARIS, Aug. 23, 2023 PARIS , Aug. 23, 2023 /PRNewswire/ -- Unither Pharmaceuticals, the world's leading manufacturer of sterile unit-dose products, recently acquired the Novartis plant in São Paulo, Brazil , as a new step in its industrial expansion in Brazil . «This acquisition enables us to benefit from sterile operations in Latin America and to enlarge our offer to...

Inflation, Rezession, Stagflation - alles Negative, was man sich bei erhöhtem Aufkommen für die Konjunktur nur vorstellen kann....

Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis PR Newswire SAN DIEGO, July 18, 2023 DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics Acquisition includes DTx-1252 with the potential to deliver a transformative medicine to Charcot-Marie-Tooth Disease Type 1A (CMT1A) patients Acquisition also includes additional early-stage programs in neuromuscular and CNS...

Shareholder Alert: Ademi LLP investigates whether Chinook Therapeutics, Inc. has obtained a Fair Price in its transaction with Novartis PR Newswire MILWAUKEE, June 12, 2023 MILWAUKEE , June 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Chinook (Nasdaq: KDNY) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis . Click here to learn how to join the action https://www.ademilaw.com/case/chinook-therapeutics-inc or call Guri Ademi toll-free at...